27677346|t|Curcumin synergistically increases effects of β-interferon and retinoic acid on breast cancer cells in vitro and in vivo by up-regulation of GRIM-19 through STAT3 - dependent and STAT3 - independent pathways
27677346|a|The study aimed to investigate the effects of combination treatment of curcumin and β-interferon (IFN-β)/ retinoic acid (RA) on breast cancer cells, including cell viability, apoptosis and migration, and to determine the mechanisms related to GRIM-19 through STAT3 - dependent and STAT3 - independent pathways. The following groups were used for the in vitro experiment: control siRNA, GRIM-19 siRNA, IFN-β / RA and IFN-β / RA + curcumin. Cell viability is by the MTT method, cell apoptosis by flow cytometry and cell migration by wound healing experiment; GRIM-19, STAT3, survivin, Bcl-2, GADD153 and COX-2 expression was measured by Western blot. In vivo experiment, MCF-7 cells were subcutaneously injected into nude mice. GRIM-19 siRNA promoted MCF-7 cell proliferation and migration; inhibited cell apoptosis; and promoted the expression of STAT3, survivin, Bcl-2 and MMP-9. IFN-β / RA inhibited cell proliferation and migration; promoted cell apoptosis; up-regulated GRIM-19; and inhibited the expression of STAT3, survivin, Bcl-2 and MMP-9. Combination treatment of curcumin and IFN-β / RA had a stronger effect than that of the IFN-β / RA group. In addition, curcumin and IFN-β / RA combination inhibited the expression of COX-2 and up-regulated GADD153. Curcumin synergistically increases the effects of IFN-β / RA on breast cancer cells. The mechanism may be related to the up-regulation of GRIM-19 through STAT3 - dependent and STAT3 - independent pathways.
27677346	0	8	Curcumin	T109,T121,T130	C0010467
27677346	9	24	synergistically	T080	C2986495
27677346	25	34	increases	T169	C0442805
27677346	35	42	effects	T080	C1280500
27677346	46	58	β-interferon	T116,T121,T129	C0015980
27677346	63	76	retinoic acid	T109,T121	C0035339
27677346	80	99	breast cancer cells	T025	C1512505
27677346	100	108	in vitro	T080	C1533691
27677346	113	120	in vivo	T082	C1515655
27677346	124	137	up-regulation	T044	C0041904
27677346	141	148	GRIM-19	T116,T126	C1448171
27677346	157	162	STAT3	T116,T123	C0253050
27677346	165	174	dependent	T080	C1701901
27677346	179	184	STAT3	T116,T123	C0253050
27677346	187	198	independent	T078	C0085862
27677346	199	207	pathways	T044	C0037080
27677346	212	217	study	T062	C2603343
27677346	218	223	aimed	T078	C1947946
27677346	227	238	investigate	T169	C1292732
27677346	243	250	effects	T080	C1280500
27677346	254	275	combination treatment	T061	C0013218
27677346	279	287	curcumin	T109,T121,T130	C0010467
27677346	292	304	β-interferon	T116,T121,T129	C0015980
27677346	306	311	IFN-β	T116,T121,T129	C0015980
27677346	314	327	retinoic acid	T109,T121	C0035339
27677346	329	331	RA	T109,T121	C0035339
27677346	336	355	breast cancer cells	T025	C1512505
27677346	367	381	cell viability	T043	C0007620
27677346	383	392	apoptosis	T043	C0162638
27677346	397	406	migration	T191	C0027627
27677346	415	424	determine	T059	C1148554
27677346	429	439	mechanisms	T044	C0678659
27677346	451	458	GRIM-19	T116,T126	C1448171
27677346	467	472	STAT3	T116,T123	C0253050
27677346	475	484	dependent	T080	C1701901
27677346	489	494	STAT3	T116,T123	C0253050
27677346	497	508	independent	T078	C0085862
27677346	509	517	pathways	T044	C0037080
27677346	533	539	groups	T078	C0441833
27677346	558	566	in vitro	T080	C1533691
27677346	567	577	experiment	T062	C0681814
27677346	579	586	control	T096	C0009932
27677346	587	592	siRNA	T114,T123	C1099354
27677346	594	601	GRIM-19	T028	C1826393
27677346	602	607	siRNA	T114,T123	C1099354
27677346	609	614	IFN-β	T116,T121,T129	C0015980
27677346	617	619	RA	T109,T121	C0035339
27677346	624	629	IFN-β	T116,T121,T129	C0015980
27677346	632	634	RA	T109,T121	C0035339
27677346	637	645	curcumin	T109,T121,T130	C0010467
27677346	647	661	Cell viability	T043	C0007620
27677346	672	682	MTT method	T062	C2986858
27677346	684	698	cell apoptosis	T043	C0162638
27677346	702	716	flow cytometry	T059	C0016263
27677346	721	735	cell migration	T043	C1622501
27677346	739	752	wound healing	T040	C0043240
27677346	753	763	experiment	T062	C0681814
27677346	765	772	GRIM-19	T116,T126	C1448171
27677346	774	779	STAT3	T116,T123	C0253050
27677346	781	789	survivin	T116,T123	C0664336
27677346	791	796	Bcl-2	T116	C0107696
27677346	798	805	GADD153	T116,T123	C0170521
27677346	810	815	COX-2	T116,T126	C1565860
27677346	816	826	expression	T045	C1171362
27677346	831	839	measured	T080	C0444706
27677346	843	855	Western blot	T059	C0949466
27677346	857	864	In vivo	T082	C1515655
27677346	865	875	experiment	T062	C0681814
27677346	877	888	MCF-7 cells	T025	C0596890
27677346	894	917	subcutaneously injected	T033	C1736929
27677346	923	932	nude mice	T015	C0025932
27677346	934	941	GRIM-19	T028	C1826393
27677346	942	947	siRNA	T114,T123	C1099354
27677346	948	956	promoted	T052	C0033414
27677346	957	967	MCF-7 cell	T025	C0596890
27677346	968	981	proliferation	T043	C0596290
27677346	986	995	migration	T191	C0027627
27677346	997	1006	inhibited	T080	C0311403
27677346	1007	1021	cell apoptosis	T043	C0162638
27677346	1027	1035	promoted	T052	C0033414
27677346	1040	1050	expression	T045	C1171362
27677346	1054	1059	STAT3	T116,T123	C0253050
27677346	1061	1069	survivin	T116,T123	C0664336
27677346	1071	1076	Bcl-2	T116	C0107696
27677346	1081	1086	MMP-9	T116,T126	C0165519
27677346	1088	1093	IFN-β	T116,T121,T129	C0015980
27677346	1096	1098	RA	T109,T121	C0035339
27677346	1099	1108	inhibited	T080	C0311403
27677346	1109	1127	cell proliferation	T043	C0596290
27677346	1132	1141	migration	T191	C0027627
27677346	1143	1151	promoted	T052	C0033414
27677346	1152	1166	cell apoptosis	T043	C0162638
27677346	1168	1180	up-regulated	T044	C0041904
27677346	1181	1188	GRIM-19	T116,T126	C1448171
27677346	1194	1203	inhibited	T080	C0311403
27677346	1208	1218	expression	T045	C1171362
27677346	1222	1227	STAT3	T116,T123	C0253050
27677346	1229	1237	survivin	T116,T123	C0664336
27677346	1239	1244	Bcl-2	T116	C0107696
27677346	1249	1254	MMP-9	T116,T126	C0165519
27677346	1256	1277	Combination treatment	T061	C0013218
27677346	1281	1289	curcumin	T109,T121,T130	C0010467
27677346	1294	1299	IFN-β	T116,T121,T129	C0015980
27677346	1302	1304	RA	T109,T121	C0035339
27677346	1311	1319	stronger	T080	C0442821
27677346	1320	1326	effect	T080	C1280500
27677346	1344	1349	IFN-β	T116,T121,T129	C0015980
27677346	1352	1354	RA	T109,T121	C0035339
27677346	1355	1360	group	T078	C0441833
27677346	1375	1383	curcumin	T109,T121,T130	C0010467
27677346	1388	1393	IFN-β	T116,T121,T129	C0015980
27677346	1396	1398	RA	T109,T121	C0035339
27677346	1399	1410	combination	T080	C0205195
27677346	1411	1420	inhibited	T080	C0311403
27677346	1425	1435	expression	T045	C1171362
27677346	1439	1444	COX-2	T116,T126	C1565860
27677346	1449	1461	up-regulated	T044	C0041904
27677346	1462	1469	GADD153	T116,T123	C0170521
27677346	1471	1479	Curcumin	T109,T121,T130	C0010467
27677346	1480	1495	synergistically	T080	C2986495
27677346	1496	1505	increases	T169	C0442805
27677346	1510	1517	effects	T080	C1280500
27677346	1521	1526	IFN-β	T116,T121,T129	C0015980
27677346	1529	1531	RA	T109,T121	C0035339
27677346	1535	1554	breast cancer cells	T025	C1512505
27677346	1560	1569	mechanism	T169	C0441712
27677346	1592	1605	up-regulation	T044	C0041904
27677346	1609	1616	GRIM-19	T116,T126	C1448171
27677346	1625	1630	STAT3	T116,T123	C0253050
27677346	1633	1642	dependent	T080	C1701901
27677346	1647	1652	STAT3	T116,T123	C0253050
27677346	1655	1666	independent	T078	C0085862
27677346	1667	1675	pathways	T044	C0037080